The perennial natural history of castration-resistant prostate cancer in the patient treated with docetaxel, cabazitaxel and abiraterone acetate

Prostate cancer is the second most frequently diagnosed cancer of men in Poland. There are two well-established primary therapeutic modalities to manage patients with early and locally advanced prostate cancer: surgical treatment and radiotherapy. Hormonal therapy is mainly used in advanced disease. The state of castration-resistant prostate cancer remains still the main therapeutic challenge. In this clinical scenario available therapeutic options are: chemotherapy (docetaxel, cabazitaxel) and new hormonal agents (abiraterone acetate, enzalutamid). The paper presents perennial natural history of prostate cancer in the patient treated with all above mentioned therapeutic methods. For the last two years the patient has recieved abiraterone acetate, which was well tolerated, with the effect of disease stabilization and quality of life improvement.